1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Deucrictibant high dose: new trials by email Literature Review of Deucrictibant high dose trials Research Report on Deucrictibant high dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II Deucrictibant low dose, Deucrictibant high dose, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Terminated | Pharvaris Netherlands B.V. | 34 | 2022-04-19 | 2026-08-17 |
Angioedemas, Hereditary (1) · Hereditary Angioedema Types I and II (1)
Pharvaris Netherlands B.V. (1)
Austria (1) · Bulgaria (1) · Canada (1) · Germany (1) · Ireland (1) · Italy (1) · Poland (1) · United Kingdom (1) · United States (1)
Marc Riedl, MD (1)